130 related articles for article (PubMed ID: 8978305)
21. Cellular interactions of CRKL, and SH2-SH3 adaptor protein.
ten Hoeve J; Kaartinen V; Fioretos T; Haataja L; Voncken JW; Heisterkamp N; Groffen J
Cancer Res; 1994 May; 54(10):2563-7. PubMed ID: 8168080
[TBL] [Abstract][Full Text] [Related]
22. Tyrosine phosphorylation of CRKL in Philadelphia+ leukemia.
ten Hoeve J; Arlinghaus RB; Guo JQ; Heisterkamp N; Groffen J
Blood; 1994 Sep; 84(6):1731-6. PubMed ID: 7521685
[TBL] [Abstract][Full Text] [Related]
23. CrkL functions as a nuclear adaptor and transcriptional activator in Bcr-Abl-expressing cells.
Rhodes J; York RD; Tara D; Tajinda K; Druker BJ
Exp Hematol; 2000 Mar; 28(3):305-10. PubMed ID: 10720695
[TBL] [Abstract][Full Text] [Related]
24. Elucidation of protein interactions necessary for the maintenance of the BCR-ABL signaling complex.
Gregor T; Bosakova MK; Nita A; Abraham SP; Fafilek B; Cernohorsky NH; Rynes J; Foldynova-Trantirkova S; Zackova D; Mayer J; Trantirek L; Krejci P
Cell Mol Life Sci; 2020 Oct; 77(19):3885-3903. PubMed ID: 31820037
[TBL] [Abstract][Full Text] [Related]
25. Mutant forms of growth factor-binding protein-2 reverse BCR-ABL-induced transformation.
Gishizky ML; Cortez D; Pendergast AM
Proc Natl Acad Sci U S A; 1995 Nov; 92(24):10889-93. PubMed ID: 7479904
[TBL] [Abstract][Full Text] [Related]
26. The SH2 domain of P210BCR/ABL is not required for the transformation of hematopoietic factor-dependent cells.
Ilaria RL; Van Etten RA
Blood; 1995 Nov; 86(10):3897-904. PubMed ID: 7579359
[TBL] [Abstract][Full Text] [Related]
27. Subcellular distribution of p210(BCR-ABL) in CML cell lines and primary CD34+ CML cells.
Patel H; Marley SB; Greener L; Gordon MY
Leukemia; 2008 Mar; 22(3):559-71. PubMed ID: 18059481
[TBL] [Abstract][Full Text] [Related]
28. BCR/ABL-induced leukemogenesis causes phosphorylation of Hef1 and its association with Crkl.
de Jong R; van Wijk A; Haataja L; Heisterkamp N; Groffen J
J Biol Chem; 1997 Dec; 272(51):32649-55. PubMed ID: 9405482
[TBL] [Abstract][Full Text] [Related]
29. A BCR-ABL mutant lacking direct binding sites for the GRB2, CBL and CRKL adapter proteins fails to induce leukemia in mice.
Johnson KJ; Griswold IJ; O'Hare T; Corbin AS; Loriaux M; Deininger MW; Druker BJ
PLoS One; 2009 Oct; 4(10):e7439. PubMed ID: 19823681
[TBL] [Abstract][Full Text] [Related]
30. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein.
Pendergast AM; Quilliam LA; Cripe LD; Bassing CH; Dai Z; Li N; Batzer A; Rabun KM; Der CJ; Schlessinger J
Cell; 1993 Oct; 75(1):175-85. PubMed ID: 8402896
[TBL] [Abstract][Full Text] [Related]
31. The tetramerization domain-independent Ras activation by BCR-ABL oncoprotein in hematopoietic cells.
Tauchi T; Okabe S; Miyazawa K; Ohyashiki K
Int J Oncol; 1998 Jun; 12(6):1269-76. PubMed ID: 9592185
[TBL] [Abstract][Full Text] [Related]
32. Deletion of the Src homology 3 domain and C-terminal proline-rich sequences in Bcr-Abl prevents Abl interactor 2 degradation and spontaneous cell migration and impairs leukemogenesis.
Dai Z; Kerzic P; Schroeder WG; McNiece IK
J Biol Chem; 2001 Aug; 276(31):28954-60. PubMed ID: 11387320
[TBL] [Abstract][Full Text] [Related]
33. LASP1 is a novel BCR-ABL substrate and a phosphorylation-dependent binding partner of CRKL in chronic myeloid leukemia.
Frietsch JJ; Kastner C; Grunewald TG; Schweigel H; Nollau P; Ziermann J; Clement JH; La Rosée P; Hochhaus A; Butt E
Oncotarget; 2014 Jul; 5(14):5257-71. PubMed ID: 24913448
[TBL] [Abstract][Full Text] [Related]
34. BCR-ABL oncoprotein is expressed by platelets from CML patients and associated with a special pattern of CrkL phosphorylation.
ten Bosch GJ; Kessler JH; Blom J; Joosten AM; Gambacorti-Passerini C; Melief CJ; Leeksma OC
Br J Haematol; 1998 Dec; 103(4):1109-15. PubMed ID: 9886328
[TBL] [Abstract][Full Text] [Related]
35. Interaction of Bcr/Abl with C3G, an exchange factor for the small GTPase Rap1, through the adapter protein Crkl.
Cho YJ; Hemmeryckx B; Groffen J; Heisterkamp N
Biochem Biophys Res Commun; 2005 Aug; 333(4):1276-83. PubMed ID: 15982636
[TBL] [Abstract][Full Text] [Related]
36. Purification and molecular cloning of SH2- and SH3-containing inositol polyphosphate-5-phosphatase, which is involved in the signaling pathway of granulocyte-macrophage colony-stimulating factor, erythropoietin, and Bcr-Abl.
Odai H; Sasaki K; Iwamatsu A; Nakamoto T; Ueno H; Yamagata T; Mitani K; Yazaki Y; Hirai H
Blood; 1997 Apr; 89(8):2745-56. PubMed ID: 9108392
[TBL] [Abstract][Full Text] [Related]
37. Structural requirements for function of the Crkl adapter protein in fibroblasts and hematopoietic cells.
Senechal K; Heaney C; Druker B; Sawyers CL
Mol Cell Biol; 1998 Sep; 18(9):5082-90. PubMed ID: 9710592
[TBL] [Abstract][Full Text] [Related]
38. Association of Bcr-Abl with the proto-oncogene Vav is implicated in activation of the Rac-1 pathway.
Bassermann F; Jahn T; Miething C; Seipel P; Bai RY; Coutinho S; Tybulewicz VL; Peschel C; Duyster J
J Biol Chem; 2002 Apr; 277(14):12437-45. PubMed ID: 11790798
[TBL] [Abstract][Full Text] [Related]
39. SHIP1, an SH2 domain containing polyinositol-5-phosphatase, regulates migration through two critical tyrosine residues and forms a novel signaling complex with DOK1 and CRKL.
Sattler M; Verma S; Pride YB; Salgia R; Rohrschneider LR; Griffin JD
J Biol Chem; 2001 Jan; 276(4):2451-8. PubMed ID: 11031258
[TBL] [Abstract][Full Text] [Related]
40. Tyrosine phosphorylation of Grb2 by Bcr/Abl and epidermal growth factor receptor: a novel regulatory mechanism for tyrosine kinase signaling.
Li S; Couvillon AD; Brasher BB; Van Etten RA
EMBO J; 2001 Dec; 20(23):6793-804. PubMed ID: 11726515
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
